Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.
James M KilgourAatman ShahNicole M UrmanShaundra EichstadtHanh N DoIrene BaileyAmar MirzaShufeng LiAnthony E OroSumaira Z AasiKavita Y SarinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The HDAC inhibitor remetinostat is a well-tolerated and effective topical treatment for reducing BCC disease burden in a clinically significant manner. This provides in-human validation of HDAC inhibitors as a therapy for BCC.